AstraZeneca: Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients With HR-Positive, HER2-Low or Negative Breast Cancer in TROPION-Breast01 Phase III Trial
September 23, 2023
September 23, 2023
WILMINGTON, Delaware, Sept. 23 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
First Phase III results in breast cancer for AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan
* * *
Plans for global regulatory submissions underway
Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant . . .
* * *
First Phase III results in breast cancer for AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan
* * *
Plans for global regulatory submissions underway
Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant . . .